The Leukemia & Lymphoma Society (LLS) and Anjin Group kicked off a three-year collaborative research program with $2.9 million. This marks the first drug development alliance to be funded through LLS' Therapy Acceleration Program (TAP).
The Anjin Group will use the money to accelerate development of a fusion toxin protein for the treatment of acute myelogenous leukemia (AML). Continued funding will depend on meeting certain milestones.
Anjin’s therapeutic platform for blood cancers, brain cancer, and other diseases is based on the fusion of a modified form of diphtheria toxin to proteins capable of selectively targeting cancerous and diseased cells. The company reports that its technology can be deployed with a variety of cell-surface receptors that are preferentially expressed on certain cell types to develop therapies with greater specificity and fewer side effects than existing drugs.